HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 16:46:53 03/06/2024 BST | ||
| 4.64 EUR | +3.57% |
|
| 1 month | +3.94% | ||
| 3 months | +107.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 4.64 | +3.57% |
| 31/05/24 | 4.48 | +4.43% |
| 30/05/24 | 4.29 | +3.12% |
| 29/05/24 | 4.16 | -2.35% |
| 28/05/24 | 4.26 | -7.19% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 04:46 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR7MNS |
| ISIN | DE000HR7MNS6 |
| Date issued | 21/05/2021 |
| Strike | 8,396 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.15 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.03 € |
| Spread % | 0.64% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
